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Abstract
Prescription drug abuse represents a national public 
health concern. This study reports on 12-month outcomes 
of a drug court treatment program for 102 female offend-
ers addicted to prescription drugs. The program utilized two 
evidence-based treatment models (i.e., Motivational En-
hancement Therapy/Cognitive Behavioral Therapy-12 and 
Seeking Safety). In addition, participants were required to 
attend monthly judicial reviews, weekly AA/NA groups, and 
two random drug screens per week. Participants were in-
terviewed at baseline and 12-month follow-up. Analyses ex-
amined self-reported substance use, traumatic experiences, 
criminal justice involvement, readiness to change, and ther-
apeutic alliance. Participants reported significant decreas-
es in substance use, increased readiness to change, high 
therapeutic alliance, and significantly fewer arrest charges 
12-months after enrollment compared to 12-months be-
fore intake. Results suggest that the drug court program 
was successful in reducing substance use and other ancil-
lary measures for female participants with prescription drug 
abuse issues. Implications for policy and future research are 
discussed.
Introduction
In Florida, more than 60% of people arrested are either un-
der the influence of drugs or alcohol or committing a crime to 
obtain narcotics [1]. However, many crimes committed by sub-
stance abusers are nonviolent [2]. Unfortunately, the criminal 
system is ill-equipped to address the underlying issues of sub-
stance abuse. All too often, untreated offenders are released 
from jail or prison only to commit more crimes related to drugs 
and alcohol, resulting in increased incarceration rates.
Of particular concern is the increase of prescription pain kill-
er abuse among arrestees. Using data from the Arrestee Drug 
Abuse Monitoring Program (ADAM), the National Survey on 
Drug Use and Health (NSDUH) reported that of those arrested 
for serious offenses within the past year, illicit drug use was re-
ported almost five times more frequently when compared to 
those not arrested within the past year [3]. When considering 
drug of choice, the nonmedical use of prescription drugs was 
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second only to marijuana. According to NSDUH, 28.8% of those 
within the sample who had committed serious criminal offenses 
within the past year reported nonmedical use of a prescription 
drug, compared to only 5.7% of those within the sample that 
had not been arrested within the past year.
Over the past decade, the availability of prescription drugs 
has increased dramatically [4]. While clinicians have an array 
of analgesics to treat pain, not all medical professionals are re-
sponsible when dispensing these powerful medications. From 
2000 to 2006, there was an 80% increase in prescription drug 
abuse; it now ranks behind only marijuana as the most abused 
drug in the U.S [5]. Recent surveys indicate almost 7 million 
Americans currently abuse prescription drugs [6]. Also, pre-
scription drugs are involved in more than 8,500 deaths per year, 
a 114% increase since 2000 [7].
There are several possible explanations for this dramatic 
upsurge in prescription drug abuse. Lax state oversight has al-
lowed unregulated and fraudulent pain clinics to proliferate, 
particularly in Florida [8]. Primary care physicians also have re-
cently expanded their prescribing of opioids [9] while pharma-
ceutical companies have introduced various new formulations 
[10]. Finally, there are few medication options for severe pain 
other than opioids [11].
Prescription drug addiction in women
Powerful prescription painkillers pose a particular threat to 
women. Unlike heroin and other street drugs, which are mainly 
abused by men, women abuse prescription drugs at least as 
often as men [12,13]. Over the past decade, two factors have 
fueled this trend: (1) women are prescribed narcotic medica-
tions more frequently than men [14] and (2) women report 
painkillers as their primary drug of abuse more often than men 
[15]. As a result, the number of addicted women in the U.S. 
continues to swell [16,17]. Not surprisingly, a segment of this 
at-risk population becomes involved in crime related to their 
prescription drug use. Women who are arrested with prescrip-
tion drug addictions are often charged with doctor shopping, 
possession of controlled substance, and drug trafficking. Facing 
additional stressors such as homelessness, unemployment, and 
inadequate child care, this population poses a daunting chal-
lenge for the traditional criminal justice system.
Drug court alternative
The punitive nature of the legal system has historically been 
ineffective in meeting the needs of most substance-abusing of-
fenders. Drug court represents a paradigm shift from punish-
ment and incarceration to treatment, rehabilitation, support, 
and community reintegration [18]. The presiding judge, sub-
stance abuse treatment provider, and offender interact on a 
regular basis in a collaborative climate. This judicial model pro-
vides better monitoring of offenders compared to other forms of 
community supervision. In return for possible dismal of charges 
or reduced probation time, the offender must adhere to his or 
her comprehensive and closely monitored treatment plan.
Drug courts reduce criminal recidivism. The results of this al-
ternative legal model are impressive. Both primary studies and 
meta-analytic reviews indicate drug courts significantly reduce 
criminal recidivism [19,20,21]. However, the evidence base sup-
porting the ability of drug courts to reduce criminal recidivism 
has been criticized for several methodological flaws [22]. Name-
ly: 1) many drug court evaluations have been methodologically 
weak, with very few rigorous experimental or quasi-experimen-
tal studies conducted; 2) previous meta-analytic reviews have 
found that, among the most methodologically rigorous studies, 
weaker evidence supporting drug courts’ effectiveness in reduc-
ing criminal recidivism has been obtained; and 3) the long-term 
duration of drug courts’ effects on criminal recidivism is also 
unclear, with many studies only following participants for 12 
months, which may or may not overlap with program participa-
tion.
The recent meta-analyses conducted by Mitchell and col-
leagues [22] on the ability of drug courts to reduce criminal 
recidivism address many of these gaps. Findings from this 
meta-analytic review support the ability of drug courts to re-
duce criminal recidivism. Although Mitchell and colleagues 
did replicate previous findings indicating higher effect sizes for 
less methodologically-rigorous evaluations, the authors note 
that all of the methodologically rigorous evaluations provided 
evidence of reduced criminal recidivism related to drug court 
participation. Also, reductions in criminal recidivism associated 
with drug court participation increased across longer durations 
of study follow-up, with the authors concluding that “the avail-
able research suggests that adult drug court participants have 
reduced recidivism during and after drug court treatment, and 
these effects appear to last at least three years post-drug court 
entry” (p. 68).
Drug courts reduce substance use. Whereas it is presumed 
that the reduction in recidivism rates for drug court participants 
is due to addressing their underlying substance use disorders, 
very few studies have directly examined participant substance 
use outcomes [23], specifically prescription drug abuse. Several 
studies have examined the effect of drug court participation 
on future drug use in general with positive effects [24,-30], but 
only two of the studies report baseline prescription drug use 
[24,29]. For example, Brewster [24] evaluated a drug court pro-
gram and compared 184 participants to 51 comparable offend-
ers. Baseline data revealed that prescription drugs were report-
ed for 4.3% of the drug court sample vs. 2.0% of the comparison 
sample with the majority reporting cocaine and marijuana as 
primary drugs of choice. Outcome results found that rates of 
positive drug tests were lower for the drug court sample than 
for the comparison sample. The second study by Messina and 
colleagues [29] compared outcomes for 150 female offenders 
who participated in either a Gender Responsive (GR) drug court 
program (N = 85) or a Mixed Gender (MG) drug court program 
(N = 65). Opiate use was reported as primary drug of choice 
for 14% overall (9% GR group vs. 20% MG group). Outcome re-
sults revealed that both the GR and MG groups had significant 
reductions in drug and alcohol composite scores from baseline 
to follow-up. Although these findings are positive, they do not 
specifically address the issue of prescription drug use in female 
offenders.
Program description
In 2008, the 6th Judicial Court received a three-year SAM-
HSA/CSAT grant to establish a drug court program serving fe-
male offenders with prescription drug abuse. The drug court 
program is titled WeCan! (Women Empowered to Cope with 
Addiction to Narcotics) and includes a judge; court-employed 
case managers; substance abuse treatment providers; defense 
attorneys; and the state Office of the Attorney General. Two 
local substance abuse treatment agencies provided 12 weeks 
of intensive outpatient treatment services using two Evidence-
Based Program (EBP) models: Motivational Enhancement 
Therapy/Cognitive Behavioral Therapy-12 (MET/CBT-12,31) and 
Seeking Safety [32]. All WeCan! participants received both EBP 
treatments regardless of which agency provided the treatment. 
The focus of MET/CBT-12 is to teach participants how to func-
tion without drugs, avoid situations that lead to drug use, and 
sensibly respond to relapses. Seeking Safety is a curriculum for 
participants with a history of trauma and substance abuse and 
focuses on coping skills and psychoeducation.
Aside from attending intensive outpatient addictions treat-
ment, all WeCan! participants were required to attend monthly 
judicial reviews, weekly AA/NA groups, and were also subjected 
to one to two random drug screens per week. Although most 
participants completed the treatment component within three 
months, most remain in drug court for judicial reviews up to 
one year. Program eligibility criteria included: (1) prescription 
drug-related charges, (2) no history of violent criminal offenses, 
(3) no diagnosis of severe mental illness, (4) no alleged sexual 
perpetration, and (5) willingness to participate in drug court 
treatment.
Current study
The current study examined preliminary treatment progress 
of female drug court participants struggling with prescription 
drug addiction. Specifically, this study utilized a 12-month longi-
tudinal design to evaluate the following hypotheses: (1) Partici-
pants will reduce substance use from baseline to 12-month fol-
low-up, (2) Participants will reduce criminal justice involvement 
from one year prior to WeCan! program enrollment to one year 
following WeCan! program enrollment, (3) Participants will in-
crease motivation and readiness to change from baseline to 12-
month follow-up, and (4) Participants will increase their thera-
peutic alliance with counselor at 12-month follow-up. Findings 
reported in this study are unique in that the WeCan! drug court 
program provided gender-specific treatment services exclusive-
ly for women struggling with prescription drug abuse issues.
Method
Procedure
This study was approved by the institutional review board at 
the University of South Florida. Baseline and 12-month follow-
up data were gathered from female offenders participating in 
the WeCan! drug court treatment program. Upon admission, 
participants completed a comprehensive intake interview that 
included several standardized measures. Participants then 
completed a follow-up interview 12-months following their en-
try to the WeCan! program. The 12-month follow-up interview 
included the standardized measures completed at baseline in 
addition to a questionnaire assessing client-therapist rapport. 
Interviews lasted approximately 90 minutes and were conduct-
ed in private.
Measures
Global Appraisal of Individual Needs [33]. The GAIN consists 
of eight core sections designed to record participant demo-
graphic and clinical characteristics. Participants completed the 
GAIN measure at baseline and at the 12-month follow-up inter-
view in order to assess change over time.
The GAIN Traumatic Stress Scale (TSS) was used to measure 
participant past-year symptoms of traumatic experiences at 
baseline. The TSS is based on the Civilian Mississippi Scale for 
PTSD and contains 13 items producing a count of symptoms 
MedDocs Publishers
3Journal of Addiction and Recovery
or memories occurring in the past year related to participant 
trauma or other disorders of extreme stress [34]. In the cur-
rent study, participant scores at baseline produced a reliability 
coefficient of 0.89. Given the different period of time assessed 
at the 12-month follow-up assessment (i.e., past 90 days versus 
past year), only baseline data for the TSS are presented.
The GAIN Past 90 Day Substance Use scale was used to mea-
sure changes in participant self-reported substance use from 
baseline to 12-month follow-up.
Criminal justice involvement. Information on participants’ 
arrest history was collected from an online database of legal 
charges in Pinellas County for the 12-month period prior to 
baseline and the 12-month period following baseline. Arrest 
charges were categorized as: (1) possession charges, (2) DUI 
charges, (3) prescription charges, (4) doctor shopping charges, 
(5) trafficking charges, (6) property charges, (7) violent charges, 
and (8) other charges. “Other charges” were less commonly ob-
served and included general criminal justice offenses such as 
violation of probation, failure to appear, and traffic violations.
Circumstances, Motivation, and Readiness [35]. The CMR is 
an 18-item instrument designed to (1) measure motivation and 
readiness for treatment and (2) predict retention in substance 
abuse treatment. Responses to each item are rated on a Likert 
scale ranging from (1) Strongly Agree to (5) Strongly Disagree. 
We utilized the instrument’s Total score as well as the Motiva-
tion scale which assessed the internal recognition of the need 
to change. Prior research produced scores with internal consis-
tencies of .60-.81 for each CMR subscale [36]. In the current 
study, participant scores at baseline produced Cronbach’s alpha 
reliability coefficients of .91 (Motivation) and. 84 (Total score).
Working Alliance Inventory [37]. The WAI is 12-item instru-
ment that assesses participants’ perspectives on the therapeu-
tic rapport between participants and service providers. Each 
item is rated on a 7-point Likert response scale. The WAI con-
tains three subscales measuring (1) the therapeutic bond, (2) 
client-provider agreement on therapeutic tasks, and (3) client-
provider agreement on therapeutic goals. There is also a com-
posite scale measuring overall working alliance. The instrument 
has been shown to produce reliable scores [38]. Meta-analytic 
studies of the WAI consistently document the relationship be-
tween a strong working alliance and positive client outcomes 
[39,40]. In the current study, the instrument was administered 
at the 12-month follow-up interview. Participant scores pro-
duced Cronbach’s alpha reliability coefficients of .74-.92 on the 
three subscales and .95 for the overall working alliance.
Analyses
Simple descriptive statistics were used to depict participant 
demographic characteristics, past-year symptoms of traumatic 
experiences, and their working relationship with their counsel-
or. Mc Nemar chi-square analyses were used to detect changes 
over time in dichotomous variables related to criminal justice in-
volvement and abstinence from alcohol and drugs. Dependent 
t-tests were used to detect changes over time for continuous 
variables related to substance use, criminal justice involvement, 
and treatment motivation. Cronbach’s alpha coefficients were 
computed to gauge the internal consistency of the standardized 
measures. Given the large number of comparisons, Bonferroni 
family-wise corrections were undertaken to control for Type I 
error inflation. All tests were two-tailed.
Results
Participants
Baseline information was collected from the first 159 female 
offenders who participated in the WeCan! program. Of these, 
102 participants (64.2% of the total sample) also completed 
measures at 12-month follow-up. To ensure the representative-
ness of the follow-up sample, analyses were performed using 
Bonferroni family-wise corrections to examine potential base-
line demographic and clinical differences between those com-
pleting only the baseline interview and those completing both 
the baseline and follow-up interviews. No significant differences 
emerged. In the absence of any significant differences, further 
analyses were restricted to the sample completing measures at 
both time points.
As can be seen in Table 1, the average age for participants 
was 30.7 years, ranging from 18 to 57. The majority of partici-
pants were Caucasian (98%) with 6.9% reporting Hispanic eth-
nicity. The majority (79.4%) had finished high school, with 43.1% 
reporting coursework beyond high school. Almost all (91.2%) 
were in a stable housing situation at baseline. Of those housed, 
41.2% reported living in a home or apartment they owned or 
rented; 50% reported living in someone else’s residence. Nearly 
half of participants (48.1%) were employed at least part-time 
at baseline. Average monthly income for participants was $887 
(SD = $877).
MedDocs Publishers
4Journal of Addiction and Recovery
Table 1: Demographics characteristics (n = 102)
Characteristic n % or Mean (SD)
Age (years) 30.7 years (9.5)
Race
  Caucasian 97 98.0
  African-American 1 1.0
  Native Hawaiian 1 1.0
Ethnicity
  Hispanic/Latino 7 6.9
Education (years) - 12.9 (2.3)
  Less than high school diploma 21 20.6
  High school diploma 37 36.3
  Some college 30 29.4
  College diploma (Bachelor’s or 
higher)
2 2.0
  Vocational technical, no diploma 1 1.0
  Vocational technical diploma 11 10.8
Housing status
  Someone else’s apartment 51 50.0
  Own/rent apartment 42 41.2
  Institution 6 5.9
  Other housed 3 3.1
Employment status
  Full-time (35 + hours a week) 32 31.4
  Part-time 17 16.7
  Unemployed, looking for work 40 39.2
  Unemployed, disabled 4 3.9
 Unemployed, not looking for work 9 8.8
Participant past-year symptoms of traumatic experiences
Table 2 presents participants’ self-reported past year symp-
toms of traumatic experiences. Of the thirteen indices of past-
year symptoms of traumatic experiences measured by the 
Traumatic Stress Scale, participants reported experiencing an 
average of 2.5 symptoms, although there was a great deal of 
variability in the number of traumatic symptoms experienced 
by participants (SD = 3.2). Participants most commonly report-
ed: 1) when something reminded them of the past, that they 
became distressed or upset (38.6%); 2) they felt guilty about 
things that happened because they felt like they should have 
done something to prevent them (36.6%); 3) they sometimes 
used alcohol or other drugs to help themselves sleep or forget 
about things that happened in the past (28.4%); 4) they had 
nightmares about things in their past that really happened 
(25.7%); and 5) they had a hard time expressing their feelings, 
even to people they cared about (24.8%). Just over a fifth of 
participants (21.8%) reported having any of the thirteen indices 
of past-year traumatic symptoms for three or more months.
Table 2: Participant past-year symptoms of traumatic experi-
ences (n = 102)
GAIN Traumatic Stress Scale Items n
% or  
M (SD)
Participant past-year symptoms of traumatic experiences
  When something reminds you of the past, you became dis-
tressed or upset
39 38.6
  You felt guilty about things that happened because you felt 
like youshould have done something to prevent them
37 36.6
  Sometimes you used alcohol or other drugs to help yourself 
sleep or forget about things that happened in the past
29 28.4
  You had nightmares about things in your past that really 
happened
26 25.7
 You had a hard time expressing your feelings, even to the 
people you cared about
25 24.8
  Your dreams at night were so real that you awoke in a cold 
sweat and forced yourself to stay awake
19 18.8
  You lost your cool and exploded over minor, everyday 
things
16 12.7
  It seemed as if you have no feelings 11 10.9
  You were frightened by your urges 9 8.9
  You felt like you could not go on 7 6.9
  You were afraid to go to sleep at night 7 6.9
  When you thought of things you had done, you wish you 
were dead
1 1.0
  Had any of the above problems for three or more months 22 21.8
Average number of TSS symptoms 2.5 (3.2)
Characteristic n % or Mean (SD)
Past 90 day Income - $887 ($877)
  Wages - $526 ($778)
  Public assistance - $112 ($225)
  Disability - $25 ($147)
  Family/friends - $119 ($251)
  Retirement - $20 ($199)
Other - $28 ($146)
   Pregnant 2 2.0
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Participant criminal justice involvement 12-months before 
and after program enrollment
Arrest data were available for all but one participant in the 
study sample. Additionally, two participants experienced their 
index offense more than 12-months before program enrollment. 
Criminal justice findings were re-analyzed excluding these cases 
with similar results obtained; however, the average number of 
charges experienced by participants in the 12-months prior to 
baseline increased due to absence of those cases with no charg-
es for this time period. Further, it should also be noted that ar-
rests which occurred during the WeCan! program did not result 
in termination from the program.
As can be seen in Table 3, a significantly smaller proportion 
of participants experienced an arrest and associated criminal 
charge(s) in the 12-months following WeCan! program entry 
(43.6%) compared to the 12-months prior to program entry 
(98.0%), χ2 (1) = 51.16, p < .001. It should be noted the num-
ber of charges exceed the number of arrests due to the fact 
that an individual may have multiple charges during one arrest 
incident. There was a significant difference in the number of ar-
rests, t (100) = 5.51, p < .001, experienced by participants in the 
12-months after program entry (M = .70, SD = 1.0) compared to 
the 12-months prior to program entry (M = 1.3, SD = 0.7). Partic-
ipants also had a significantly lower average number of charges 
over time, t (100) = 4.68, p < .001, experienced by participants 
at 12-months after program entry (M = 1.5, SD = 3.0) compared 
to 12-months prior to program entry (M = 3.3, SD = 2.7). 
Most participants (67.3%) had a prior arrest for possession 
charges compared to only 19.8% 12-months after program en-
try, χ2 (1) = 42.48, p < .001. There were several additional sta-
tistically significant reductions in other types of charges in the 
12-months including: prescription fraud charges, χ2 (1) = 5.79, p 
= .016; DUI charges, χ2 (1) = 9.10, p = .003; trafficking charges, χ2 
(1) = 4.90, p = .028; and doctor shopping charges, χ2 (1) = 8.10, 
p = .004. Other decreases in the number of charges incurred by 
participants observed included the average number of posses-
sion charges, t (99) = 4.39, p < .001; prescription fraud charges, 
t (100) = 2.88, p = .005; DUI charges, t (100) = 3.30, p = .001; 
doctor shopping charges, t (100) = 2.66, p = .005; and property 
charges, t (100) = 2.23, p = .028.
Table 3: Participant criminal justice involvement 12-months before and 12-months following program enrollment (n = 102)
Participants with arrest history data
12-months before program  
enrollment
12-months following program 
enrollment
Significance1
na % M (SD)b na % M (SD)b
Total arrests 99 98.02 44 43.6 <.001
1.3 (0.7) 0.7 (1.0) <.001
Total charges 99 98.0 44 43.6 <.001
3.3 (2.7) 1.5 (3.0) <.001
  Possession charges 68 67.3 20 19.8 <.001
3.3(2.7) 0.6 (1.6) <.001
  Prescription fraud charges 16 15.8 6 5.9 .016
0.3 (0.8) 0.1 (0.3) .009
  DUI charges 13 12.9 2 2.0 .003
1.4 (1.5) 0.0 (0.2) .001
  Doctor shopping charges 11 10.9 1 1.0 .004
0.4 (1.5) 0.0 (0.1) .005
  Trafficking charges 13 12.9 1 1.0 .003
0.2 (0.7) 1.0 (0.6) .128
  Property charges 16 15.8 8 7.9 .080
0.2 (0.6) 0.1 (0.4) .028
  Violent charges 7 7.1 1 1.0 .077
0.1 (0.5) 0.0 (0.1) .060
  “Other” charges 22 22.0 23 23.0 .999
0.4 (1.1) 0.6 (1.7) .264
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Note: Some missing data; valid percentages displayed.
1. A Bonferroni family-wise correction was made to control for likelihood of Type I error inflation. Specifically, the significance level for main study 
hypotheses related to proportion of participants experiencing any arrest and any charge as well as total number of arrests and total number 
of charges over time was adjusted to p = .0125 (.05 / 4 tests). No Bonferroni family-wise corrections were made for subsequent exploratory 
analyses related to likelihood as well as total number of specific charges incurred by participants over time; subsequent exploratory analyses 
were evaluated at p < .05. Significant p-values are bolded.
2. Arrest data were accessible for all but one participant whose case was closed. It should be noted that some participants’ (n = 2) original 
offense(s) that brought them into drug court occurred more than 12-months before their entry into the Program; hence that information was not 
captured in this study’s arrest data
a.Percentages represent the percent of participants with one or more of the arrests/charges indicated.
b. Measures of central tendency are based on the average number of arrests/charges experienced by the sample.
Participant substance use in past 90 days
Table 4 presents information of participants’ self-reported 
substance use. WeCan! participants reported significant reduc-
tions in alcohol and illicit drug use from baseline to 12-month 
follow-up. At baseline, 60.8% of participants reported alcohol 
use within the past 90 days; 12-months later only 15.7% did 
(χ2 [1] = 37.50, p <.001). At baseline, 79.4% of participants re-
ported illicit drug use within the past 90 days; 12-months later 
only 18.6% did (χ2 [1] = 60.02, p <.001). Specifically, 38.2% of 
participants reported marijuana use within the past 90 days at 
baseline vs. only 2.0% at 12-month follow-up (χ2 [1] = 35.03, 
p <.001). In terms of prescription drug use, 46.1% of partici-
pants reported use at baseline; 12-months later only 6.9% (χ2 
[1] = 38.03, p <.001). Specifically, 38.2% of participants reported 
painkiller/opiate use within the past 90 days at baseline vs. only 
5.9% at 12-month follow-up (χ2 [1] = 31.03, p <.001). Additional-
ly, 27.5% of participants reported anti-anxiety/tranquilizer use 
within the past 90 days at baseline vs. only 3.9% at 12-month 
follow-up (χ2 [1] = 18.89, p <.001). There also were significant 
reductions for alcohol (t [100] = 4.17, p< .001),marijuana (t [100 
= 3.84, p< .001), painkillers/opiates (t [100] = 3.94, p< .001), and 
anti-anxiety/tranquilizers (t [101] = 2.92, p = .004).
Table 4: Substance use change over time from baseline to 12-month follow-up (n = 102)
Baseline 12-month Significance1
n % or M (SD) n % or M (SD)
Percent of participants using past 90 days:
 Alcohol 62 60.8 16 15.7 <.001
 Illicit drugs 81 79.4 19 18.6 <.001
 Marijuana 39 38.2 2 2.0 <.001
 Crack 6 5.9 3 2.9 .371
 Cocaine 6 5.9 3 2.9 .505
 Heroin 2 2.0 0 0.0 a
 Prescription drugs 47 46.1 7 6.9 <.001
 Pain killers, opiates 39 38.2 6 5.9 <.001
 Anti-anxiety, tranquilizers 28 27.5 4 3.9 <.001
 Downers, sedatives 2 2.0 1 1.0 .999
Number of days in past 90 using: 
  Alcohol 7.0 (14.4) 0.9 (3.3) <.001
  Illicit drugs2
  Marijuana 6.2 (16.4) 0.3(3.0) <.001
  Crack 0.6 (3.3) 0.1 (0.5) .119
  Cocaine 0.2 (1.2) 0.1 (0.5) .368
  Heroin 0.5 (4.5) 0.0 (0.0) .289
  Prescription drugs2
  Pain killers, opiates 10.9 (23.9) 2.0 (9.9) <.001
  Anti-anxiety, tranquilizers 3.4 (11.2) 0.3 (2.0) .004
  Downers, sedatives 0.1 (1.0) 0.1 (1.4) .909
Note: Some missing data; valid percentages displayed.
1. Two Bonferroni family-wise corrections were made to control for likelihood of Type I error inflation, separated by 
type of analyses (percentage of participants using specific substances in the past 90 days; number of days participants 
Participant ratings of therapeutic alliance
In conjunction with these findings, participants reported 
strong relationships with their court-appointed counselors. 
Participants reported positive working relationships regarding 
treatment task (M = 23.1 [SD = 4.9]), bond with their counselor 
(M = 22.8 [SD = 6.5]), treatment goals (M = 22.3 [SD = 4.9]), and 
overall working alliance with their counselor (M = 68.2 [SD = 
15.5]).
Discussion
This 12-month evaluation study of a therapeutic drug court 
tailored for female offenders with prescription drug abuse is-
sues examined participant self-reported substance use and 
symptoms of traumatic experiences, criminal justice involve-
ment, motivation and readiness to change, and therapeutic alli-
ance. Results of this study supported the appropriateness of the 
treatment modality employed to address participant substance 
use. Specifically, the WeCan! program incorporated a treatment 
modality specifically tailored to deal with the relationship be-
tween substance abuse and trauma symptoms [32]. At base-
line, participants reported high levels of self-reported past-year 
trauma symptoms and endorsed several items including using 
alcohol or drugs as a coping strategy. These results support the 
need for targeted interventions to provide trauma-informed 
care for substance use disorders.
WeCan! participants significantly reduced their criminal jus-
tice involvement over the course of their first year of participa-
tion when compared to the year prior to their WeCan! involve-
ment. There was a significant decrease in the total number of 
participant arrests that occurred in the 12-months before pro-
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reported using specific substances in the past 90 days). Specifically, the significance level related to the proportion of 
participants using specific substances was adjusted to p = .005 (.05 / 10 tests); the significance level related to the 
number of days participants reported using specific substances was adjusted to p = .00625 (.05 / 8 tests). P-values for 
significant tests are bolded.
2. It was not possible to create a composite variable regarding the number of days participants reported any type of 
drug use in the past 90 days.
a. Could not be computed as one variable was a constant
Table 5: Participant scores on the Circumstances, Motivation, Readiness (CMR) scale from baseline to 12-
month follow-up (n = 102)
Baseline 12-month Significance1
M (SD) M (SD)
Motivation
  Internal recognition of the need to change 16.2 (6.8) 22.9 (5.6) <.001
Total score 54.0 (13.8) 70.5(23.9) <.001
Note: Some missing data; valid percentages displayed. Analyses are restricted to only the CMR subscale 
Motivation as well as the CMR Total Score scale given the poor reliability of scores produced for other CMR 
subscales (i.e., Circumstances 1, Circumstances 2, and Readiness for Treatment).
1. A Bonferroni family-wise correction was made to control for likelihood of Type I error inflation. Specifically, the 
significance level was adjusted to p = .025 (.05 / 2 tests). P-values for significant tests are bolded.
gram entry compared to 12-months after program enrollment. 
In the 12-months prior to program entry, the most common 
arrest charge incurred by participants was drug possession. 
However, only a small percentage of participants had posses-
sion charges 12-months after program enrollment. Additionally, 
participants also had significant reductions in DUI, prescription 
fraud charges, doctor shopping, and trafficking charges. Results 
from this study documenting reduced criminal behavior for We-
Can! participants are consistent with the large body of litera-
ture supporting the ability of drug courts to reduce participant 
criminal recidivism [22].
WeCan! participants also significantly reduced their levels 
of self-reported substance use across the 12-months after their 
program entry. This is impressive considering the length of treat-
ment is approximately three to four months and reductions in 
alcohol and drug use decreased significantly at 12-month fol-
low-up. This improvement included the substances most com-
monly abused by participants in the past: alcohol, marijuana, 
and prescription painkillers. This study adds to the small but 
growing body of literature supporting the ability of drug courts 
to reduce participant substance use.
Participants reported significantly increased motivation or 
internal recognition of the need to change at 12-month follow-
up. Additionally, most participants were pleased with the thera-
peutic bond developed with program staff. They felt there was 
a shared client-counselor vision regarding therapeutic tasks and 
goals. These findings are particularly impressive given the po-
tential for coercive relationships when engaged in the judicial 
system and support the professionalism of treatment providers. 
Participant circumstances, motivations, and readiness 
(CMR)
As seen in Table 5, participants reported significantly in-
creased motivation at 12-month follow-up (M = 22.9 [SD = 5.6]) 
than at baseline (M = 16.2 [SD = 6.8]), t (66) = -6.22, p< .001. 
Participants also reported significantly higher total scores on 
the CMR from baseline (M = 54.0, SD = 13.8) to 12-month fol-
low-up (M = 70.5, SD = 23.9), t (63) = -4.60, p< .001.
It is likely that high participant motivation, strong working alli-
ances, and a positive therapeutic environment all contributed 
to reduced substance use over the course of the study period.
Limitations
Conclusions based on this program evaluation are restricted 
by the use of a pretest-posttest study design without a com-
parison group. Another limiting factor is the reliance on un-
verifiable, self-report data related to past substance use. This 
limitation is further compounded by the serious legal ramifica-
tions for non-compliance (e.g., self-reported drug use) faced 
by drug court participants. Finally, it is impossible to determine 
the long-term outcomes for WeCan! participants based on this 
study’s 12-month follow-up. Future research should follow of-
fenders for several years after program graduation.
Conclusions
Study findings suggest that the WeCan! program is meeting 
programmatic goals for its target population of female offend-
ers with prescription drug abuse issue. Increasing numbers of 
female offenders abusing prescription painkillers are burden-
ing an already overtaxed legal system. Innovative programs like 
WeCan! offer a fundamentally different way of dealing with a 
problem that threatens the public health of many communities 
across the United States, especially in Florida. The significant 
reductions in substance use and criminal justice involvement 
suggest this type of program should be of particular interest to 
policymakers in these difficult economic and social times. As-
suming future research replicates the positive findings of this 
study, specialized drug courts could help reshape the judicial 
system in the coming decades. While the cost of quality sub-
stance abuse treatment is high, the costs of ongoing addiction, 
incarceration, and criminal recidivism are much higher—both in 
dollars spent and lives lost.
References
1. National Institute of Justice. 2000 Arrestee Drug Abuse 
Monitoring: Annual Report. Washington, D.C: U.S. De-
partment of Justice. 2003.
2. Supreme Court Task Force on Treatment-Based Drug 
Courts . Report on Florida’s Drug Courts. Tallahassee, FL: 
Office of the State Courts Administration/Office of Court 
Improvement. 2004.
3. Office of Applied Studies, SAMHSA. Results from the 2004 
National Survey on Drug Use and Health. 2005.
4. Volkow ND. Scientific Research on Prescription Drug 
Abuse Judiciary Committee. Subcommittee on Crime and 
Drugs, US Senate. 2008.
5. Office of National Drug Control Policy. (ONDCP). Prescrip-
tion Drugs Facts & Figures. 2008.
6. Substance Abuse Mental Health Services Administration 
(SAMHSA ). Results from the 2011 National Survey on 
Drug Use and Health: Summary of National Findings, NS-
DUH Series H-44. 2012.
7. Office of National Drug Control Policy (ONDCP). Prescrip-
tion Opioid-related Deaths Increased 114 Percent from 
2001 to 2005. 2009.
8. Wisniewski AM, Purdy CH, Blondell RD. The epidemiologic 
association between opioid prescribing, non-medical use, 
MedDocs Publishers
8Journal of Addiction and Recovery
and emergency department visits. J Addict Disord. 2008; 
27: 1–11.
9. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers, 
EL, et al. Use of opioid medications for chronic non cancer 
pain syndromes in primary care, J Gen Intern Med. 2006; 
17: 173–179.
10. Goodman FD, Glassman P. Evaluating potentially aberrant 
outpatient prescriptions for extended-release oxycodone. 
American Journal of Health-System Pharmacy. 2005; 62: 
2604-2608.
11. Brands B, Blakea J, Sproula B, Gourlaya D, Bustoa U. Pre-
scription opioid abuse in patients presenting for metha-
done maintenance treatment. Drug and Alcohol Depen-
dence. 2004; 73: 199-207.
12. Kelly JP, Cook SF, Kaufman DW, Anderson T, Rosenberg L, 
Mitchell AA. Prevalence and characteristics of opioid use 
in the US adult population. Pain. 2008; 138: 507–513.
13. Simoni-Wastila L. Ritter G, Strickler G. Gender and other 
factors associated with the nonmedical use of abusable 
prescription drugs. Substance Use and Misuse. 2004; 39: 
1-23.
14. Isacson D, Bingefors K. Epidemiology of analgesic use: a 
gender perspective. European J Anesthesiol. 2012; 19: 
5-15.
15. Office of Applied Studies, SAMHSA. The DASIS Report. 
How Men and Women Enter Substance Abuse Treatment. 
2001.
16. Cicero TJ, Lynskeya M, Todorova A, Inciardib JA., Surratth 
HL. Co-morbid pain and psychopathology in males and fe-
males admitted to treatment for opioid analgesic abuse. 
Pain. 2008; 139: 127-135.
17. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, 
Sullivan LE. Gender and non-medical use of prescription 
opioids: results from a national US survey. Addict. 2008; 
103: 258–268.
18. Stinchcomb J. Drug courts: Conceptual foundation, em-
pirical findings, and policy implications. Drugs: Education, 
Prevention, and Policy. 2010; 17: 148-167.
19. Belenko S. The challenges of integrating drug treatment 
into the criminal justice process, Albany Law Review. 
2000; 63: 833–876.
20. Shaffer DK. Looking inside the black box of drug courts: 
A meta-analytic review. Justice Quarterly. 2011; 28: 493–
521.
21. Wilson DB, Mitchell O, Mackenzie DL. A systematic review 
of drug court effects on recidivism. Journal of Experimen-
tal Criminology. 2006; 2: 456-487.
22. Mitchell O, Wilson DB, Eggers A, MacKenzie DL. Assessing 
the effectiveness of drug courts on recidivism: A meta-
analytic review of traditional and non-traditional drug 
courts. J Crim Justice. 2012; 40: 60-71.
23. Green M, Rempel M. Beyond crime and drug use: Do adult 
drug courts produce other psychosocial benefits? Journal 
of Drug Issues. 2012; 42: 156-177.
24. Brewster MP. An evaluation of the Chester County (PA) 
Drug Court Program. Journal of Drug Issues. 2011; 31: 
177-206.
25. Gott fredson DC, Kearley B, Najaka SS, Rocha CM. The Bal-
timore City Drug Treatment Court: 3-year outcome study. 
Evaluation Review. 2005; 29: 42-64.
26. Harrell A, Roman J, Sack E. Drug court services for female 
offenders: Evaluation of the Brooklyn Treatment Court. 
Washington, DC: The Urban Institute. 2001; 1996-1999.
27. Marchand G, Waller M, Carey SM. Barry County Adult 
Drug Court Outcome and Cost Evaluation. Portland, OR: 
NPC Research. 2006a.
28. Marchand G, Waller M, Carey SM. Kalamazoo County 
Adult Drug Treatment Court Outcome and Cost Evalua-
tion. Portland, OR: NPC Research. 2006b.
29. Messina N, Calhoun S, Warda U. Gender-response drug 
court treatment: A randomized controlled trial. Criminal 
Justice & Behavior. 2012; 39: 1539-1558.
30. Rossman SB, Roman JK, Zweig JM, Lindquist CH, Rempel 
M, et al. The Multi-Site Adult Drug Court Evaluation: Study 
Overview and Design. Washington, DC: Urban Institute. 
2016. 
31. Miller WR, Rollnick S. Motivational Interviewing: Prepar-
ing People to Change Addictive Behavior. New York: Guil-
ford Press. 1995.
32. Najavits L. Seeking Safety: A Treatment Manual for PTSD 
and Substance Abuse. New York: Guilford Press. 2002.
33. Dennis ML, White MK, Titus JC, Unsicker JI. Global Ap-
praisal of Individual Needs (GAIN): Administration Guide 
MedDocs Publishers
9Journal of Addiction and Recovery
for the GAIN and Related Measures (Version 5). Bloom-
ington, IL: Chestnut Health Systems. 2006.
34. Dennis ML, Ives M, Funk R, Modisette K, Bledsaw R, Ih-
nes P. GAIN-I Encyclopedia of Supplemental Documenta-
tion on Scales and Other Calculated Variables. Normal, IL: 
Chestnut Health Systems. 2010.
35. De Leon, G, Melnick G, Kressel D. Motivation and readiness 
for therapeutic community treatment among cocaine and 
other drug abusers. American J Drug and Alcohol Abuse. 
1997; 23: 169–189.
36. De Leon G, Melnick G, Hawke J. The motivation-readiness 
factor in drug treatment: Implications for research and 
policy. In: D. McBride (Ed.), Emergent Issues in the Field 
of Drug Abuse. 2000; 7: pp103-129. 
37. Horvath AO, Greenberg LS. Development and validation 
of the Working Alliance Inventory. Journal of Counseling 
Psychology. 1989; 36: 223-233.
38. Horvath AO. Empirical validation of Bordin’spantheoretical 
model of the alliance: The Working Alliance Inventory per-
spective. In A.O. Horvath and L.S. Greenberg (Eds.), The 
Working Alliance: Theory, Research, and Practice). New 
York, NY: Wiley. 1994; pp109-128
39. Horvath AO, Symonds BD. Relation between working al-
liance and outcome in psychotherapy: A meta-analysis. 
Journal of Counseling Psychology. 1991; 38: 139-149.
40. Martin DJ, Garske JP, Davis MK. Relation of the therapeu-
tic alliance with outcome and other variables: A meta-
analytic review. J Consulting and Clin Psychol. 2000; 68: 
438-450.
